A huge congratulations to BenchSci for closing a $95-million Series D raise!
The round was led by Al Gore’s Generation Investment Management. Existing BenchSci investors such as Inovia Capital, TCV, Golden Ventures, and F-Prime Capital also participated in the round.
The company will use the latest funding to expand its revolutionary AI drug discovery platform which enables scientists to discover biological connections, dramatically reduce trial-and-error experimentation and uncover risks early.
Today, BenchSci’s software is used by 16 of the top 20 pharmaceutical companies and by over 50,000 scientists working at more than 4,500 leading research centers worldwide making it a world leader in AI solutions for preclinical life sciences R&D.
BenchSci is a superstar in the TSFV portfolio. We invested in the company in their pre-seed raise with our very first fund in 2016 and are proud to have supported them on their journey ever since.
Congratulations to BenchSci Co-Founder and CEO Liran Belenzon and the entire team! Your work is making a positive impact across the world.
